Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 44.15M P/E - EPS this Y 2.10% Ern Qtrly Grth -
Income -27.21M Forward P/E -1.92 EPS next Y 53.90% 50D Avg Chg -2.00%
Sales 4.09M PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 1.74 EPS next 5Y - 52W High Chg -42.00%
Recommedations 2.30 Quick Ratio 0.26 Shares Outstanding 9.23M 52W Low Chg 131.00%
Insider Own 19.03% ROA -41.84% Shares Float 3.36M Beta 0.79
Inst Own 38.87% ROE -118.62% Shares Shorted/Prior 20.89K/39.05K Price 0.84
Gross Margin - Profit Margin - Avg. Volume 240,174 Target Price 20.00
Oper. Margin -420.00% Earnings Date Mar 29 Volume 14,557 Change 2.54%
About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SAB Biotherapeutics, Inc. News
06:15 AM SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
03/25/24 SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
02/23/24 SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
02/08/24 SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/02/24 SAB Biotherapeutics Announces Executive Leadership Change
01/23/24 SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
01/05/24 Individual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last week
01/02/24 SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
01:29 PM SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment
07:30 AM SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
11/20/23 SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
11/14/23 SAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financing
11/14/23 SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
11/14/23 SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
11/09/23 SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
10/24/23 SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
10/19/23 SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
10/05/23 SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
10/03/23 SAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatment
10/02/23 SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
SABS Chatroom

User Image DDiamond_Handz Posted - 23 hours ago

$SABS resistance sitting between 6.50- 7.00, if we can break through there we are in a whole new ball game

User Image DWolo24 Posted - 1 day ago

$AVTX $SABS is next to squeeze

User Image PokerTrader2 Posted - 1 day ago

$SABS getting so tired of playing baby pharmas. When’s the next R/S? It’s being crushed by entities who work for big pharma that want this company on the cheap. Pure bullsh!t

User Image TraderJackson_ Posted - 2 days ago

$DOMA $INBS $IFBD $SABS BREAKING OUT 🕸️

User Image FinnessaurusFlex Posted - 2 days ago

$LUNR bout to 🚀🚀🚀 then moving some funds to $ASTS $SABS $IONQ

User Image DDiamond_Handz Posted - 2 days ago

$SABS she's gunna turn around

User Image Stocksrunner Posted - 3 days ago

Monday's Meltdown! $VMEO plunged with no apparent news, leaving traders scratching their heads $AEHR tumbled as preliminary Q3 results missed estimates. $CGC high from Germany's legal weed news went up in smoke as the stock dropped $INTZ rang the alarm bells with looming earnings. $SABS took a hit despite its naval research partnership for a potential flu treatment.

User Image DDiamond_Handz Posted - 3 days ago

$SABS today is just a sell the news charade. This thing will pump later this week once all the whales get their discount basement bargain pricing.

User Image RRGM Posted - 3 days ago

$SABS the price action could be connected to what happened last time SABS worked with the government- got totally effed with.

User Image Stoccksz Posted - 3 days ago

$SABS is this a good news or no ? Why is it down?

User Image kenbkb Posted - 3 days ago

$SABS Partnering with the Navy is obviously not the good news investors have been looking for.

User Image DutchVH Posted - 3 days ago

$SABS 👀

User Image Vetiver Posted - 3 days ago

$SABS Now where is the fool calling me a liar when I posted, weeks ago, that SAB -176 is still in the program?! https://www.biospace.com/article/releases/sab-biotherapeutics-announces-clinical-partnership-with-naval-medical-research-center-to-advance-potential-influenza-treatment/

User Image Nicks_pics Posted - 3 days ago

$SABS “Intramuscular administration”. I’m not a Dr., so need some guidance here. My understanding is that would be a simple shot? I’d we can move away from the intravenous administration of polyclonal antibodies, we can crossover to mainstream global use. If this Navy trial works out, we could finally end up with a marketable flu product.

User Image Stock_Titan Posted - 3 days ago

$SABS $SABSW SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment https://www.stocktitan.net/news/SABS/sab-biotherapeutics-announces-clinical-partnership-with-naval-xofoa2mcfpbx.html

User Image Nicks_pics Posted - 6 days ago

$SABS Somebody fess up. Who bought 4 shares and ruined our perfect 100 share trading day?

User Image Nicks_pics Posted - 6 days ago

$SABS Lowest trading volume I have ever seen on one of my tickers today. Hope it's the calm before the storm.

User Image DDiamond_Handz Posted - 6 days ago

$SABS average daily volume has been abysmal. I thought Eddie's replacement was going to fix things not make it worse.. starting to get worried this is going to be a sequel to the Ji show

User Image DDiamond_Handz Posted - 1 week ago

$SABS its supposed to be green today

User Image DDiamond_Handz Posted - 2 weeks ago

$SABS

User Image DDiamond_Handz Posted - 2 weeks ago

$SABS punctured bottom trendline couple weeks ago but seems to be turn back up now within range. Guessing around June/July we see a technical breakout if there's no big developments before then

User Image DDiamond_Handz Posted - 2 weeks ago

$SABS https://www.tipranks.com/news/company-announcements/sab-biotherapeutics-secures-leadership-with-new-executive-contracts?utm_source=webullapp.com&utm_medium=referral

User Image RRGM Posted - 3 weeks ago

$SABS does anyone know if there was a provision in the warrants for a pro rata adjustment to the strike price? Read about a case called Rebot where warrants were still exercisable at original price after R/S.

User Image DDiamond_Handz Posted - 3 weeks ago

$SABS

User Image _StockTrader Posted - 3 weeks ago

Real-Time Stock Data $SABS Price: 4.65 Volume: 15200 Market Cap: 44879624 PE Ratio: -2.5077317 Stock data provided by: PSYC

User Image DDiamond_Handz Posted - 3 weeks ago

$SABS

User Image DDiamond_Handz Posted - 4 weeks ago

$SABS maybe this was all just the dip before the rip, almost always happens in biotech before a large run 🤞

User Image Nathaniel_Hoernblower Posted - 1 month ago

$SABS down 30% since my last monthly check in. Guessing they'll be broke in 4 - 6 months. Holding on at this point. Do I still get the tax loss benefit when the stock price hits zero, or do i actually have to sell before that?

User Image moulinsart Posted - 1 month ago

$SABS this stock is going nowhere, been holding forever and nothing good happens beside dilution

User Image DDiamond_Handz Posted - 1 month ago

$SABS

Analyst Ratings
HC Wainwright & Co. Buy Jan 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sullivan Eddie Joe Chief Executive Offi.. Chief Executive Officer Dec 07 Buy 0.88 1,740 1,531 5,232,304 12/08/23
King Michael CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Nov 30 Buy 0.900 5,000 4,500 5,000 11/30/23
HAMILTON CHRISTINE E Director Director Sep 13 Buy 0.7297 10,000 7,297 4,993,090 09/14/22
Sullivan Eddie Joe CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 07 Buy 0.7368 14,000 10,315 5,230,564 09/08/22